Ahmedabad-based drugmaker Zydus Lifesciences plans to launch its semaglutide injection manufacturers upon patent expiry of the drug in India. The drugmaker stated it can launch the drug in a novel single-pen machine that’s reusable. Zydus has unique rights to the machine.
The patent for semaglutide is ready to run out on 20 March 2026, with a number of Indian drugmakers together with Dr. Reddy’s and Solar Pharma gearing up for Day-one launches.
Zydus has acquired regulatory approval from the Drug Controller Normal of India (DCGI) to market and manufacture semaglutide to deal with type-2 diabetes and weight problems.
The drug shall be launched below model names Semaglyn, Mashema, and Alterme, the corporate stated in a launch on Wednesday.
Whereas the corporate didn’t share its pricing technique, it stated the single-pen machine would decrease the general value of remedy by permitting sufferers to manage various dose strengths from the identical machine.
“A important differentiator of Zydus’ semaglutide providing shall be its novel, indigenously developed drug supply system. In contrast to present remedies that require sufferers to buy a number of single-dose pens as they titrate their dosage, Zydus plans to introduce an progressive, adjustable single-pen machine,” the corporate stated.
Intensifying race
The announcement comes as competitors amongst drugmakers to realize an edge within the profitable market intensifies. Earlier this week, Eris Lifesciences and Natco Pharma introduced a partnership to commercialize semaglutide.
Cipla and Emcure have additionally introduced distribution offers with innovators Eli Lilly and Novo Nordiskrespectively, whereas Solar Pharma and Dr. Reddy’s have already began exporting it to non-patented markets after receiving the Delhi Excessive Court docket’s nod, they usually plan to launch the drug in India upon patent expiry.
Glucagon-like peptide-1 (GLP-1) medicine similar to semaglutide have already crossed ₹1,000 crore in gross sales in lower than a 12 months of launches in India. At present, innovator medicine Mounjaro, Wegovy and Ozempic dominate, however the entry of generic variations of semaglutide, priced decrease, is predicted to additional increase the market.